{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:17:50Z","timestamp":1782451070862,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00259-020-04938-0","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T23:03:51Z","timestamp":1593471831000},"page":"3066-3073","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Comparison of simultaneous 18F-2-[18F] FDG PET\/MR and PET\/CT in the follow-up of patients with differentiated thyroid cancer"],"prefix":"10.1007","volume":"47","author":[{"given":"Michele","family":"Klain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Nicolai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandra","family":"Piscopo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Gaudieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Zampella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cavaliere","family":"Carlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schlumberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3431-7658","authenticated-orcid":false,"given":"Alberto","family":"Cuocolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"4938_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1\u2013133.","journal-title":"Thyroid"},{"key":"4938_CR2","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1210\/jc.2005-1534","volume":"91","author":"RJ Robbins","year":"2006","unstructured":"Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F] Fluoro-2-Deoxy-D-glucose positron emission tomography. J Clin Endocrinol Metab. 2006;91:498\u2013505.","journal-title":"J Clin Endocrinol Metab"},{"key":"4938_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1677\/ERC-10-0233","volume":"18","author":"D Deandreis","year":"2011","unstructured":"Deandreis D, Al Ghuzlan A, Leboulleux S, Lacroix L, Garsi JP, Talbot M, et al. Do histological, immunohistochemical and metabolic (radioiodine and fluorodeoxyglucose uptake) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer. 2011;18:159\u201369.","journal-title":"Endocr Relat Cancer"},{"key":"4938_CR4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1089\/thy.2014.0320","volume":"25","author":"C Nascimento","year":"2015","unstructured":"Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Hartl D, Lumbroso J, et al. Post-operative fluorine-18-fluorodeoxyglucose positron emission tomography\/computed tomography (FDG-PET\/CT): an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. Thyroid. 2015;25:437\u201344.","journal-title":"Thyroid"},{"key":"4938_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40336-017-0254-7","volume":"5","author":"L Pace","year":"2017","unstructured":"Pace L, Klain M, Tagliabue L, Storto G. The current and evolving role of FDG-PET\/CT in personalized iodine 131 therapy of differentiated thyroid cancer. Clin Transl Imaging. 2017;5:533\u201344.","journal-title":"Clin Transl Imaging"},{"key":"4938_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/ncpendmet0402","volume":"3","author":"S Leboulleux","year":"2007","unstructured":"Leboulleux S, Schroeder PR, Schlumberger M, Ladenson PW. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab. 2007;3:112\u201321.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"4938_CR7","first-page":"503","volume":"53","author":"L Pace","year":"2009","unstructured":"Pace L, Nicolai E, Klain M, Salvatore M. Diagnostic value of FDG PET\/CT imaging. Q J Nucl Med Mol Imaging. 2009;53:503\u201312.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"4938_CR8","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s11547-014-0474-0","volume":"120","author":"Q Chen","year":"2015","unstructured":"Chen Q, Raghavan P, Mukherjee S, Jameson MJ, Patrie J, Xin W, et al. Accuracy of MRI for the diagnosis of metastatic cervical lymphadenopathy in patients with thyroid cancer. Radiol Med. 2015;120:959\u201366.","journal-title":"Radiol Med"},{"key":"4938_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.23736\/S1824-4785.17.02961-2","volume":"63","author":"P Vera","year":"2019","unstructured":"Vera P, Edet-Sanson A, Quieffin F, Le Cloirec J, Bertrand AS, Cailleaux M, et al. Diffusion-weighted MRI is not superior to FDG-PET\/CT for the detection of neck recurrence in well-differentiated thyroid carcinoma. Q J Nucl Med Mol Imaging. 2019;63:311\u201320.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"4938_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1089\/thy.2007.0135","volume":"18","author":"L Seiboth","year":"2008","unstructured":"Seiboth L, Van Nostrand D, Wartofsky L, Ousman Y, Jonklaas J, Butler C, et al. Utility of PET\/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer. Thyroid. 2008;18:103\u201311.","journal-title":"Thyroid"},{"key":"4938_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40336-013-0012-4","volume":"1","author":"L Pace","year":"2013","unstructured":"Pace L, Nicolai E, Aiello M, Catalano OA, Salvatore M. Whole-body PET\/MRI in oncology: current status and clinical applications. Clin Transl Imaging. 2013;1:31\u201344.","journal-title":"Clin Transl Imaging"},{"key":"4938_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40644-016-0096-y","volume":"16","author":"JM Hempel","year":"2016","unstructured":"Hempel JM, Kloeckner R, Krick S, Pinto Dos Santos D, Schadmand-Fischer S, Boe\u00dfert P, et al. Impact of combined FDG-PET\/CT and MRI on the detection of local recurrence and nodal metastases in thyroid cancer. Cancer Imaging. 2016;16:37.","journal-title":"Cancer Imaging"},{"key":"4938_CR13","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s00259-015-3195-2","volume":"43","author":"A Vrachimis","year":"2016","unstructured":"Vrachimis A, Burg MC, Wenning C, Allkemper T, Weckesser M, Schafers M, et al. [(18)F]FDG PET\/CT outperforms [(18)F]FDG PET\/MRI in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016;43:212\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4938_CR14","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s00259-013-2580-y","volume":"41","author":"A Varoquaux","year":"2014","unstructured":"Varoquaux A, Rager O, Poncet A, Delattre BM, Ratib O, Becker CD, et al. Detection and quantification of focal uptake in head and neck tumors: (18)F-FDG PET\/MR versus PET\/CT. Eur J Nucl Med Mol Imaging. 2014;41:462\u201375.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4938_CR15","first-page":"1366","volume":"45","author":"G Sgouros","year":"2004","unstructured":"Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, et al. Patient specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med. 2004;45:1366\u201372.","journal-title":"J Nucl Med"},{"key":"4938_CR16","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00259-015-3288-y","volume":"43","author":"I Binse","year":"2016","unstructured":"Binse I, Poeppel TD, Ruhlmann M, Gomez B, Umutlu L, Bockisch A, et al. Imaging with (124)I in differentiated thyroid carcinoma: is PET\/MRI superior to PET\/CT? Eur J Nucl Med Mol Imaging. 2016;43:1011\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4938_CR17","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1007\/s00259-016-3334-4","volume":"43","author":"L Dercle","year":"2016","unstructured":"Dercle L, Deandreis D, Terroir M, Leboulleux S, Lumbroso J, Schlumberger M. Evaluation of (124)I PET\/CT and (124)I PET\/MRI in the management of patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016;43:1006\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4938_CR18","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. European Association of Nuclear Medicine (EANM). FDG PET\/CT: EANM procedure guidelines for tumor imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4938_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12880-016-0143-y","volume":"16","author":"B Quinn","year":"2016","unstructured":"Quinn B, Dauer Z, Pandit-Taskar N, Schoder H, Dauer LT. Radiation dosimetry of 18F-FDG PET\/CT: incorporating exam-specific parameters in dose estimates. BMC Med Imaging. 2016;16:41.","journal-title":"BMC Med Imaging"},{"key":"4938_CR20","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1089\/thy.2012.0081","volume":"22","author":"S Leboulleux","year":"2012","unstructured":"Leboulleux S, El Bez I, Borget I, Elleuch M, Deandreis D, Lumbroso J, et al. Post-radioiodine treatment whole body scan in the era of fluorodesoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels. Thyroid. 2012;22:832\u20138.","journal-title":"Thyroid"},{"key":"4938_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1530\/EJE-19-0261","volume":"181","author":"Q Wan","year":"2019","unstructured":"Wan Q, Bai L, Zhao G, Zhang Y, Ma Q, Wang R, et al. Diagnostic performance of 18F-FDG-PET\/CT in DTC patients with thyroglobulin elevation and negative iodine scintigraphy: a meta-analysis. Eur J Endocrinol. 2019;181:93\u2013102.","journal-title":"Eur J Endocrinol"},{"key":"4938_CR22","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1210\/jc.2002-021365","volume":"88","author":"E Baudin","year":"2003","unstructured":"Baudin E, Docao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up following thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab. 2003;88:1107\u201311.","journal-title":"J Clin Endocrinol Metab"},{"key":"4938_CR23","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1210\/jc.2002-021925","volume":"88","author":"F Pacini","year":"2003","unstructured":"Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:3668\u201373.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-04938-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-020-04938-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-04938-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T23:26:19Z","timestamp":1625009179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-020-04938-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":23,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4938"],"URL":"https:\/\/doi.org\/10.1007\/s00259-020-04938-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"assertion":[{"value":"27 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (Ethics Committee of the National Cancer Institute of Naples, Protocol number 2-11, IRCCS-SDN) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed written consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}